Aprea Therapeutics, Inc.
APRE
$1.84
-$0.0799-4.16%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -21.04% | -41.96% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -21.04% | -41.96% | |||
| Cost of Revenue | 5.26% | -17.12% | |||
| Gross Profit | -7.77% | 13.58% | |||
| SG&A Expenses | 64.52% | -33.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.78% | -22.91% | |||
| Operating Income | -26.65% | 21.26% | |||
| Income Before Tax | -35.85% | 23.49% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -35.85% | 23.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -35.85% | 23.49% | |||
| EBIT | -26.65% | 21.26% | |||
| EBITDA | -26.69% | 21.29% | |||
| EPS Basic | -34.97% | 23.69% | |||
| Normalized Basic EPS | -34.99% | 23.69% | |||
| EPS Diluted | -34.97% | 23.69% | |||
| Normalized Diluted EPS | -34.99% | 23.69% | |||
| Average Basic Shares Outstanding | 0.66% | 0.25% | |||
| Average Diluted Shares Outstanding | 0.66% | 0.25% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||